Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

Study Purpose

Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are few effective treatments for MM(multiple myeloma). BCMA (B cell maturation antigen) is a promising target for malignant plasma cells. Therefore, we designed a clinical trial using anti-BCMA CAR-T cell therapy for patients with relapsed and refractory multiple myeloma.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

Subjects must meet the following criteria for inclusion in the study: 1) Male or female subjects between the ages of 18 and 75(including critical values); 2) Subjects histologically confirmed as relapsed and refractory multiple myeloma. Positive expression of BCMA(>50%) in malignant plasma cells; Approved anti-tumor therapies, such as systemic chemotherapy, systemic radiotherapy, and immunotherapy, have been completed for at least 2 weeks before the precondition. ECOG≤1; Life expectancy ≥ 3 months; Neutrophil absolute count ≥ 1×10^9/L; platelet count ≥ 50×10^9/L; Absolute lymphocyte count ≥ 1×10^8/L ; Adequate organ function reserve : GPT, GST ≤ 2.5× UNL(upper normal limit); Creatinine clearance (Cockcroft Gault method)≥60mL/min; Serum total bilirubin ≤1.5× UNL; The left ventricular ejection fraction (LVEF) ≥ 50% was diagnosed by echocardiography, and there was no clinically significant pericardial effusion and ECG abnormality; Basic oxygen saturation in indoor natural air environment > 92%; It can establish the venous access needed for collection without the contraindications of leukocyte collection; For female subjects of childbearing age, results are negative in urine pregnancy test before screening and administration, and subjects agree to take effective contraceptive measures at least one year after infusion; Male subjects with partners' fertility must agree to use effective barrier contraceptive methods at least one year after infusion, and avoid sperm donation; Voluntary signing of informed consent;

Exclusion Criteria:

Any of the following points shall be deemed as no entry into this study: Other tumors except cured non-melanoma skin cancer, cervical cancer in situ, superficial bladder cancer, breast duct cancer in situ, or other malignant tumors with complete remission of more than 5 years); Severe mental disorders; A history of genetic diseases such as Fanconi anemia, Shudder-Dale syndrome, Costman syndrome, or any other known bone marrow failure syndrome; Heart disease with grade III-IV heart failure [NYHA classification], myocardial infarction, angioplasty or stenting, unstable angina or other heart diseases with prominent clinical symptoms within one year before admission; Subjects with any indwelling catheter or drainage tube (such as percutaneous nephrostomy tube, bile drainage tube or pleura/peritoneum/pericardium catheter), should be excluded. (Special central venous catheter is allowed); Subjects with a history of CNS lymphoma, CSF malignant cells, or brain metastasis; Subjects with a history of CNS disease,such as epilepsy, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving CNS; Any of the following virological ELISA results are positive: HIV antibody, HCV antibody, TPPA, HBsAg; Active infection requiring systematic treatment within 2 weeks before single collection; Subjects with known severe allergic reactions to cyclophosphamide or fludarabine, or diagnosed as the allergy; History of autoimmune diseases (e.g. Crohn disease, rheumatoid arthritis, systemic lupus erythematosus) that cause end-organ damage or require systemic immunosuppressive medications or systemic disease modifying drugs in the past 2 years; Presence of pulmonary fibrosis; Subjects who have received other clinical trial treatment within 4 weeks before participating in this trial should be excluded. Or the signing date of informed consent is within 5 half-lives of the last application of another clinical trial (whichever is longer); Subjects with poor compliance due to physiological, family, social, geographical and other factors, or those unable to cooperate with the study plan or follow-up; At the discretion of the investigator, there are complications requiring systemic corticosteroid therapy (≥ 5mg / day of prednisone or equivalent dose of other corticosteroids) or other immunosuppressive drugs within 6 months after this clinical research treatment; The lactating woman who is reluctant to stop breastfeeding; Any other condition considered unsuitable by the investigator.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04637269
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Early Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Xinqiao Hospital of Chongqing
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Xi Zhang
Principal Investigator Affiliation Xinqiao Hospital of Chongqing
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

OtherIndustry
Overall Status Recruiting
Countries China
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Multiple Myeloma
Arms & Interventions

Arms

Experimental: BCMA CAR-T

The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the "3 + 3" dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.

Interventions

Biological: - anti-BCMA CAR-T

5×10^7 /KG 15×10^7 /KG 45×10^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

ChongQing, Chongqing, China

Status

Recruiting

Address

Department of Hematology, Xinqiao Hospital

ChongQing, Chongqing, 400037